Edwards Lifesciences Corporation

• Valuation1.5 / 10
• Management8.5 / 10
• Balance Sheet8.5 / 10
• Profitability5.5 / 10
• Revenue Growth6 / 10
• Risk Assessment8 / 10
• Competitive Moat9 / 10
• Earnings Quality6 / 10
• Capital Efficiency6.5 / 10

Valuation disconnect drives our Sell rating. The valuation composite weights forward earnings at 30% ($65.84 midpoint), enterprise discounted cash flow at 25% ($44.02 midpoint), and multi-stage moat fade at 25% ($71.83 midpoint), supported by owner earnings ($40.04) and peer-adjusted PEG analysis ($95.61). Edwards' 25.64x forward P/E multiple trades at an excessive premium to medical technology peers such as Boston Scientific (12.55x), Stryker (16.48x), and Regeneron (11.99x).^1,2,3,4,6

Structural heart moat remains intact but growth is bounded by hospital capacity. Edwards generated $6,067.6M in FY2025 revenue, anchored by its US franchise which contributed $3,543.1M or 58.39% of total sales, alongside $1,517.5M from Europe. The business retains an industry-leading gross margin of 78.01% ($4,733.4M gross profit) and operating profitability of $1,264.2M, insulated by clinical switching barriers and SAPIEN operator familiarity. However, executive commentary during Q2 2026 confirmed that clinical practice evolves slowly and National Coverage Determination (NCD) updates will have minimal immediate impact on 2026 procedure volume. Hospital catheterization lab staffing bottlenecks and administrative onboarding pace capacity expansions, capping medium-term US TAVR growth in the mid-to-high single digits.^5,7,8

Capital cycle reinvestment and balance-sheet liquidity provide financial durability. Edwards deployed $260.2M in capital expenditures in FY2025 (1.66x D&A), tracking consistent prior investments of $253.0M in FY2023 and $252.4M in FY2024. Annual operating cash flow of $1,595.2M covers capex by 6.1x, generating $1,335.0M in free cash flow and funding $158.1M in stock-based compensation offsets. With low debt of $704.4M and 0.893 adjusted beta, the enterprise has no solvency risk. Nevertheless, market expectations embed an implied growth rate of 16.82% per reverse DCF analysis against the approved 11.45% base forecast, creating severe de-rating vulnerability if multiple compression toward peer levels occurs.^2,4,6,7

Actionable positioning recommendations. Under committee rating authority, investors should divest or trim existing equity positions, rotating capital toward attractively valued peers. While third-party consensus targets average $100.96 ($92.66 present-value equivalent), this sell-side divergence reflects uncalibrated multiple maintenance.

Accelerated implementation of finalized National Coverage Determination (NCD) policies opens substantial hospital cath lab capacity and center access, reigniting US TAVR procedural growth while early-stage asymptomatic indication expansions broaden the eligible patient population. Emerging transcatheter mitral and tricuspid therapies scale rapidly, lifting consolidated gross margin and operating margin. Normalizing capex intensity relative to revenue expands annual cash flows, driving accelerated share repurchases and compound earnings expansion.^1,5

Forecast cash flows / share

8,76 US$

Terminal value / share

29,15 US$

Signed net debt / current share

-6,11 US$